Changes in the national prevalence of asthma and coronavirus disease 2019 fatality: A population-based cross-sectional study

BACKGROUND: The coronavirus disease 2019 (COVID-19) mitigation and containment strategies implemented by each country can influence the prevalence of asthma and its fatality. OBJECTIVE: To analyze the trend of asthma prevalence and COVID-19 fatality in children and adults with asthma. METHODS: The prevalence of asthma and fatalities were compared among the peaks of 5 pandemic waves in Mexico. RESULTS: Among patients with COVID-19, the prevalence rates of asthma among children were as follows: wave I, 3.5%; wave II, 2.6%; wave III, 2.2%; wave IV, 2.4%; and wave V, 1.9% (P for trend < .001); the prevalence rates of asthma among adults were as follows: wave I, 2.5%; wave II, 1.8%; wave III, 1.5%; wave IV, 1.7%; and wave V, 1.6% (P for trend < .001). The rates of fatality because of COVID-19 among individuals with asthma were as follows: wave I, 8.9%; wave II, 7.7%; wave III, 5.0%; wave IV, 0.9%; and wave V, 0.2% (P for trend < .001). CONCLUSION: The prevalence rates of asthma and fatalities from COVID-19 suggest a gradual reduction throughout the pandemic in Mexico.